India's first indigenous dengue vaccine, DengiAll, in advanced Phase 3 clinical trials
India's first indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec and supported by the Indian Council of Medical Research (ICMR), is nearing completion of its third phase clinical trials. Approximately 8,000 out of 10,000 targeted participants have enrolled across 20 centres nationwide. The vaccine aims to provide effective efficacy against all four dengue serotypes circulating in India. Dengue is a significant public health concern globally and in India, with high incidence and potential for severe conditions like hemorrhagic fever. Currently, there is no antiviral treatment or licensed vaccine for dengue in India.
Key Points
- India's first indigenous tetravalent dengue vaccine, DengiAll, is undergoing Phase 3 clinical trials.
- The trials are a collaborative effort between the Indian Council of Medical Research (ICMR) and Panacea Biotec Ltd.
- The vaccine aims to provide efficacy against all four serotypes of the dengue virus, which co-circulate in India.
- Dengue is a major public health concern in India, ranking among the top 30 countries globally for incidence.
- There is currently no antiviral treatment or licensed vaccine available for dengue in India.
Exam Facts
- The vaccine is named DengiAll.
- It is a tetravalent dengue vaccine strain (TV003/TV005).
- Developed by Panacea Biotec and supported by ICMR.
- Approximately 8,000 participants enrolled in Phase 3 trials across 20 centres.
- Dengue virus has four serotypes (1-4).
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.